No doubt many will have read that erectile dysfunction affects many men across the world, maybe as high as 1 in 10.
One of the main problems is the embarrassment and false stigma attached to erectile dysfunction (ED). This can leave many men overwhelmingly anxious when it comes to performing in the bedroom. The knock on effect can be partners feeling shut out and maybe even unloved. This is quite clearly not the case, but it does become a vicious circle. It is difficult for some men to discuss the problems with their partners as if it undermines their masculinity. It doesn’t!read more
The drug industry, which has done a masterful job convincing men to get help for impotence, is looking to the next frontier in male sexuality — premature ejaculation.
Johnson & Johnson, the big drug manufacturer, plans to ask the federal Food and Drug Administration next year to approve a pill for premature ejaculation, which, by various estimates, affects 20 percent to 30 percent of men at some point in their lives.read more
Kristi Vlahos, a pharmacist at the Jonestown Pharmacy in Winston-Salem, is used to seeing scams come across her counter.
The last one, an advertisement faxed to her pharmacy, advertised a birth-control patch. The patch, which is worn on a patients’ body, functions much like a birth-control pill and can control a woman’s ovulation cycle.read more
Despite some strong early sales numbers and tens of millions of dollars in advertising, Cialis is coming up short.
When Icos (ICOS:Nasdaq – news – research) and Eli Lilly (LLY:NYSE – news – research) kicked off the U.S. launch of their much-hyped impotence drug in November 2003, optimists said the drug — nicknamed “the weekender” because of its 36-hour potency — would quickly leapfrog over Pfizer’s (PFE:NYSE – news – research) Viagra and GlaxosmithKline’s (GSK:NYSE ADR – news – research) Levitra.read more
The makers of Cialis have been saying for more than six months they think customers will like their drug for erectile dysfunction better than the competitors, Viagra and Levitra.
But now Bothell-based Icos and its partner Eli Lilly are doing more than talk. In what is believed to be a first for the pharmaceutical industry, the companies today are starting a national ad campaign that offers to buy patients one of the competing drugs if they aren’t completely satisfied with their first sample of Cialis.read more
Satisfaction guaranteed or we’ll pay you to buy from our competitors! Sounds like a slick used-car salesman’s gimmick, doesn’t it?
Actually, it’s Eli Lilly (NYSE: LLY) and Icos’ (Nasdaq: ICOS) pitch for their drug Cialis. You can probably figure out what the companies mean by “satisfaction” just by knowing that the drug treats erectile dysfunction (ED). The “Cialis Promise” promotion offers a free trial of the drug for men who have never used it before and promises that participants not pleased with the results will receive a voucher for a competing product, presumably GlaxoSmithKline (NYSE: GSK) and Bayer’s (NYSE: BAY) Levitra and/or Pfizer’s (NYSE: PFE) Viagra.read more
SEATTLE — Icos, the Bothell biotech company, and partner Eli Lilly said yesterday the erectile dysfunction drug Cialis had $137 million in worldwide sales in the second quarter.
The sales breakdown showed it had $51 million in U.S. sales in its second full quarter on the market, and $45 million in sales in Europe, where it has been available for more than a year. Cialis has reached $245 million in worldwide sales through the first half of the year, and the companies say it is on track to reach their forecast of $500 million to $600 million in worldwide sales this year.read more